Skip to main content
. 2022 Jan 25;14:100308. doi: 10.1016/j.lanepe.2022.100308

Figure 5.

Figure 5

Forest plot depicting standardised probability ratios of initiating either a SGLT-2i or a GLP-1RA at time of first intensification according to income group and subgroups between 2018 and 2020.

CI, confidence interval; CV disease, cardiovascular disease defined as ischemic heart disease, peripheral artery disease, stroke, or heart failure; GLP-1RA, glucagon-like-peptide-1 receptor agonist; SGLT-2i, sodium-glucose cotransporter-2 inhibitor.